Journal of Evidence-Based Medicine, Journal Year: 2024, Volume and Issue: 17(3), P. 559 - 574
Published: Aug. 19, 2024
Conflicting results have been reported about the impact of neoadjuvant therapy on anastomotic leakage (AL) after esophagectomy. We aimed to unravel potential effect AL esophagectomy through a network meta-analysis.
Language: Английский
Journal of Thoracic and Cardiovascular Surgery, Journal Year: 2024, Volume and Issue: 168(2), P. 417 - 428.e3
Published: Jan. 19, 2024
Language: Английский
Citations
20
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: Feb. 7, 2023
Purpose Neoadjuvant chemoimmunotherapy (nCIT) is becoming a new therapeutic frontier for resectable esophageal squamous cell carcinoma (ESCC); however, crucial details and technical know-how regarding surgical techniques the perioperative challenges following nCIT remain poorly understood. The study investigated compared advantages disadvantages of esophagectomy with neoadjuvant chemotherapy (nCT) chemoradiotherapy (nCRT). Methods We retrospectively analyzed data patients initially diagnosed ESCC at clinical stage T2-4N+ received therapy followed by Hunan Cancer Hospital between October 2014 February 2021. Patients were divided into three groups according to treatment: (i) nCIT; (ii) nCT; (iii) nCRT. Results There 34 in group, 97 nCT 31 nCRT group. Compared nCT, achieved higher pathological complete response (pCR; 29.0% versus 4.1%, p<0.001) major (MPR; 52.9% 16.5%, rates, more resected lymph nodes during surgery (25.06 ± 7.62 20.64 9.68, p =0.009), less intraoperative blood loss (200.00 73.86 266.49 176.29 mL, =0.035), comparable results other parameters. nCRT, similar pCR (29.0% 25.8%) MPR (52.9% 51.6%, p=0.862) significantly 16.94 7.24, p<0.001), shorter operation time (267.79 50.67 306.32 79.92 min, =0.022), 264.53 139.76 fewer ICU admissions after (29.4% 80.6%, p<0.001). Regarding adverse events complications, no significant statistical differences detected or groups. 3-year overall survival rate was 73.3%, slightly than 46.1% 39.7% statistically (p=0.883). Conclusions This analysis showed that safe feasible, satisfactory rates. Esophagectomy has several over morbidity mortality. long-term benefits still requires further investigation.
Language: Английский
Citations
25
Journal of Thoracic and Cardiovascular Surgery, Journal Year: 2024, Volume and Issue: 169(1), P. 289 - 300.e6
Published: June 27, 2024
Language: Английский
Citations
7
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: May 12, 2023
Objective This systematic review and meta-analysis aimed to investigate the role of neoadjuvant immunochemotherapy with or without radiotherapy [NIC(R)T] compared traditional therapies, immunotherapy [NC(R)T]. Summary background data NCRT followed by surgical resection is recommended for patients early-stage esophageal cancer. However, it uncertain whether adding preoperative therapy would improve patient outcomes when radical surgery performed following therapy. Methods We searched PubMed, Web Science, Embase, Cochrane Central databases, as well international conference abstracts. Outcomes included R0, pathological complete response (pCR), major (mPR), overall survival (OS) disease-free (DFS) rates. Results from 5,034 86 studies published between 2019 2022. found no significant differences NICRT in pCR mPR Both were better than NICT, NCT showing lowest rate. Neoadjuvant has a advantage over terms 1-year OS DFS, NICT having any other three treatments. There among four treatments R0 Conclusions Among treatment modalities, had highest rates Adding improved modalities. Systematic Review Registration https://inplasy.com/inplasy-2022-12-0060/ , identifier INPLASY2022120060.
Language: Английский
Citations
12
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: Nov. 14, 2023
Objectives The treatment of locally advanced oral or oropharyngeal squamous cell carcinoma (LAOOPSCC) is surgery and radiotherapy chemoradiotherapy but with unsatisfactory survival rate. Neoadjuvant programmed death-1 (PD-1) therapy are being used in several clinical trials. Therefore, this retrospective study we aimed to determine the feasibility neoadjuvant tislelizumab plus chemotherapy followed by for LAOOPSCC. Materials methods data 33 patients LAOOPSCC who received PD-1 inhibitors between April 2021 October 2022 were retrospectively analyzed. Patients stage III-IV tislelizumab, albumin-bound paclitaxel, cisplatin every 3 weeks (Q3W) two cycles, adjuvant concurrent chemoradiotherapy. A median follow-up period was 20 months. Results objective response rate (ORR) 66.7%, major pathological (MPR) at 54.5%, complete (pCR) 33.3%. Sixteen underwent limited surgeries, 15 remitted from undergoing mandibulectomy 9 near total glossectomy glossectomy. significant difference overall (OS) disease-free (DFS) observed achieved than did not. most common adverse events alopecia, decreased appetite anorexia, leukopenia, fatigue. Conclusion combined feasible safe, a high possible organ preservation carcinoma. However, further studies larger cohort longer required strengthen our findings evaluate benefits treatment.
Language: Английский
Citations
11
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15
Published: Jan. 6, 2025
Neoadjuvant chemoimmunotherapy (NCIT) has improved pathological complete response and conferred survival benefits in patients with locally advanced esophageal cancer. However, surgical complications unrelated to the tumor continue detract from patient outcomes. While "watch-and-wait" strategy been implemented clinical responders following neoadjuvant therapy for rectal cancer, there is a lack of evidence supporting its practicability cancer after NCIT. This pilot case series involves six who deferred surgery under close surveillance three or four cycles camrelizumab plus chemotherapy subsequently received as maintenance treatment. The primary observation measure event-free (EFS). Routine follow-up examinations included endoscopy, biopsy, contrast-enhanced computed tomography, ultrasonography every 3-6 months. For experienced local recurrence without metastasis, salvage operation was priority recommendation. As September 5, 2024, average duration 124.4 weeks, EFS reaching 134.7 weeks. No deaths distant metastases were observed. Our findings suggest that NCIT may be spared esophagectomy. On prerequisite sufficient regression during cycles, immunotherapy facilitate continued eradication residual disease this series.
Language: Английский
Citations
0
Cancer Immunology Immunotherapy, Journal Year: 2025, Volume and Issue: 74(5)
Published: March 15, 2025
Improving pathological complete response (pCR) rate is currently the main goal of neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (LA-ESCC). However, improved pCR rates do not consistently translate into better prognosis, likely due to regimen-specific heterogeneity. We investigated this heterogeneity and potential biomarkers between two common regimens. included 445 LA-ESCC patients from four centers, with 228 receiving chemoradiotherapy (nCRT) 217 undergoing chemotherapy combined immunotherapy (nICT). Propensity score matching ensured group comparability. assessed their associations overall survival (OS), disease-free (DFS), recurrence patterns. Immune-related were through RNA sequencing immune infiltration analysis, then validated via multiplex immunofluorescence staining. Overall, was associated significantly higher DFS (HR = 0.3 [0.18–0.5], P < 0.01) OS 0.19 [0.08–0.41], compared non-pCR. The nICT had a lower than nCRT (27.2% vs. 42.9%) but demonstrated comparable prognosis reduced distant metastasis. Among patients, in 0.2 [0.05–0.86], 0.031), trend toward OS. Immune analysis revealed increased CD8 + T infiltration, particularly CD69 tissue-resident memory cells (TRM), group. proportion TRM linked (P 0.016) 0.015), suggesting they may be superior prognostic markers rates. obtained different treatments has distinct outcomes. TRM, as predictor, warrants further investigation.
Language: Английский
Citations
0
Journal for ImmunoTherapy of Cancer, Journal Year: 2025, Volume and Issue: 13(3), P. e011149 - e011149
Published: March 1, 2025
Background Accurate prediction of pathologic complete response (pCR) following neoadjuvant immunotherapy combined with chemotherapy (nICT) is crucial for tailoring patient care in esophageal squamous cell carcinoma (ESCC). This study aimed to develop and validate a deep learning model using novel voxel-level radiomics approach predict pCR based on preoperative CT images. Methods In this multicenter, retrospective study, 741 patients ESCC who underwent nICT followed by radical esophagectomy were enrolled from three institutions. Patients one center divided into training set (469 patients) an internal validation (118 while the data other two centers was used as external sets (120 34 patients, respectively). The model, Vision-Mamba, integrated feature maps images prediction. Additionally, commonly models, including 3D-ResNet Vision Transformer, well traditional methods, developed comparison. Model performance evaluated accuracy, area under curve (AUC), sensitivity, specificity, prognostic stratification capabilities. SHapley Additive exPlanations analysis employed interpret model’s predictions. Results Vision-Mamba demonstrated robust predictive (accuracy: 0.89, AUC: 0.91, sensitivity: 0.82, specificity: 0.92) 0.83–0.91, 0.83–0.92, 0.73–0.94, 0.84–1.0). outperformed models methods. ability stratify high low-risk groups validated, showing superior compared SHAP provided quantitative visual interpretation. Conclusions We present radiomics-based pretreatment diagnostic accuracy robustness. could provide promising tool individualized management ESCC.
Language: Английский
Citations
0
European journal of medical research, Journal Year: 2025, Volume and Issue: 30(1)
Published: April 11, 2025
Esophageal squamous cell carcinoma (ESCC) stands among the frequently occurring malignancies. The lack of efficient early detection methods and therapeutic approaches leads to a high mortality rate for ESCC. long noncoding RNA MIR210HG is strongly related various malignant tumors. However, its involvement in ESCC remains unexplored. Thus, this investigation aimed assess development. expression was analyzed numerous tumor types through pan-cancer analysis Cancer Genome Atlas(TCGA) database. This research investigated role survival prognosis individuals with biological functions were examined by enrichment analyses, including GO, GSEA, KEGG. Moreover, immune infiltration, microenvironment (TME) characteristics, checkpoint levels associated explored. To get more insight into connection between ESCC, we assessed gene protein using Western blotting qRT-PCR. evaluate proliferation, invasion, migration, apoptosis, autophagy cells, techniques employed, EdU proliferation tests, monodansylcadaverine (MDC) staining, wound healing assays, colony formation, transwell flow cytometry, an established xenograft mouse model. exhibited low High correlated higher patients. elevated hindered cell's ability proliferate, invade, migrate, both vivo vitro settings. Furthermore, positive correlation P53 signaling pathway observed, which could affect apoptosis cells. emerges as pivotal influencing immunity it may via pathway. Overall, these outcomes present novel ideas treatment.
Language: Английский
Citations
0
Surgical Endoscopy, Journal Year: 2025, Volume and Issue: unknown
Published: April 23, 2025
Language: Английский
Citations
0